MiMedx Group, Inc.
MDXGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 29, 2026 | Mizuho Securities | Anthony Petrone | $7.00(+77%) | $3.95 | StreetInsider |
| Aug 27, 2026 | Craig-Hallum | $8.00(+76%) | $4.54 | TheFly | |
| Aug 17, 2026 | Raymond James | Sarah James | $8.00(+89%) | $4.23 | StreetInsider |
| Jul 30, 2026 | Lake Street | $7.00(+76%) | $3.98 | TheFly | |
| Feb 23, 2026 | UBS | $10.00(+93%) | $5.17 | StreetInsider | |
| Nov 15, 2024 | Mizuho Securities | Anthony Petrone | $16.00(+76%) | $9.09 | StreetInsider |
| Jul 2, 2024 | Cantor Fitzgerald | Ross Osborn | $11.00(+64%) | $6.70 | TheFly |
| Apr 29, 2024 | Lake Street | Brooks O'Neil | $12.00(+92%) | $6.26 | TheFly |
| Sep 7, 2022 | H.C. Wainwright | $8.00(+134%) | $3.42 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Craig-Hallum | maintain | Buy | Aug 27, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 17, 2026 |
| Citizens | maintain | Market Outperform | Apr 30, 2026 |
| Citizens | maintain | Market Outperform | Apr 20, 2026 |
| Craig-Hallum | maintain | Buy | Apr 17, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Feb 17, 2026 |
| Lake Street | maintain | Buy | Jan 20, 2026 |
| Mizuho | maintain | Outperform | Dec 17, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Jul 31, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Jul 15, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Feb 27, 2025 |
| Craig-Hallum | maintain | Buy | Aug 1, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Aug 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2024 |
| Mizuho | maintain | Buy | Mar 1, 2024 |
| Mizuho | maintain | Buy | Oct 31, 2023 |
| Mizuho | maintain | Buy | Aug 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 21, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2023 |
| Mizuho | maintain | Buy | Oct 13, 2022 |
| HC Wainwright & Co. | maintain | Buy | Sep 7, 2022 |
| HC Wainwright & Co. | maintain | Buy | Sep 14, 2021 |
| Northland Capital Markets | maintain | Outperform | Jul 26, 2021 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $0.02| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $-0.01 | $0.00 | $62.3M | $68.6M |
| Jul 29, 2026 | $-0.05 | $-0.05 | $64.4M | $63.5M |
| Apr 29, 2026 | $-0.05 | $-0.07 | $59.0M | $65.8M |
| Feb 25, 2026 | $0.14 | $0.09 | $118.1M | $106.8M |
| Oct 29, 2025 | $0.15 | $0.07 | $113.7M | $101.9M |
| Jul 30, 2025 | $0.10 | $0.06 | $98.6M | $90.6M |
| Apr 30, 2025 | $0.06 | $0.06 | $88.2M | $86.3M |
| Feb 26, 2025 | $0.07 | $0.07 | $92.9M | $89.4M |
News
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
MiMedx Group NASDAQ: MDXG reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical revenue rose 9% year over year to $40 million, while wound care revenue declined 71% to $22 million following Medicare reimbursement changes that took effect at the beginning of 2026.
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter During Quarter Today Announced Patent License Agreement, Underscoring Strength of IP Portfolio Management to Host Conference Call Today, October 28, 2026, at 4:30 PM ET MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (…
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX's patents.
BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares BioNTech and MiMedx Group's net
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
MiMedx Group, Inc (NASDAQ: MDXG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among
Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Compugen and
MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Institutional and Insider Ownership 79.2% of MiMedx Group
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this consi.
MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Deutsche Bank AG bought a new position in shares of MiMedx Group, Inc (NASDAQ: MDXG) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 135,153 shares of the company's stock, valued at approximately $520,000. Deutsche Bank AG owned about